IP Library Granted Patent US 9,381,190
Granted Patent B2
US 9,381,190 · App. 14/634,689 · Granted Jul 5, 2016

Melatonin tablet and methods of preparation and use

Inventor: John A. McCarty (Miami Springs, FL)
Assignee: PHARMACEUTICAL PRODUCTIONS INC.
A61K31/4045A61K9/0056A61K9/143A61K9/2009A61K9/2013A61K9/2018A61K9/2031A61K9/2095A61K31/40A61K31/70
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,381,190
App. No.
14/634,689
Granted
Jul 5, 2016
Kind
B2
Abstract

The present invention provides a pharmaceutical composition for sublingual or buccal administration of actives with low to poor aqueous solubility, e.g. the indole hormone melatonin, which contains a solution of the active in a pharmaceutically acceptable solvent adsorbed or absorbed onto particles of a pharmaceutically acceptable carrier and methods of preparing and using the pharmaceutical composition.

Claims (14)

1. A tablet for sublingual or buccal administration of melatonin, said tablet comprising:

melatonin in a dissolved state;

a solvent which is polyethylene glycol (PEG) 200, 300, 400, and or 600; and

a pharmaceutically acceptable carrier to which the dissolved melatonin is adsorbed and which becomes a flowable powder, the carrier being silica or calcium silicate;

where in melatonin is in a dissolved state in the tablet, and

wherein the drug dissolution from the tablet is substantially complete within 15 minutes.

2. The tablet of claim 1 , in which the concentration of melatonin solubilized in the solvent is in the range of about 5% w/w to about 30% w/w.

3. The tablet of claim 1 , wherein the weight:weight ratio of carrier to melatonin solution is in the range of about 1:0.5 to about 1:4.

4. The tablet of claim 1 , further comprising a diluent, a disintegrant, and/or a lubricant.

5. A process for the preparation of the tablet of claim 1 , comprising the steps of:

dissolving melatonin in the PEG to form a drug solution; and

mixing the drug solution with the pharmaceutically acceptable carrier silica or calcium silicate to adsorb said solution to the carrier particles forming a flowable powder; and

compressing the solution-adsorbed carrier particles into a tablet.

6. The process of claim 5 , further comprising adding additional excipients to the solvated melatonin/adsorbent before compressing the solvated, adsorbed melatonin/adsorbent particles into the form of a tablet.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 22, 2015
From: MCCARTY, JOHN A.
To: PHARMACEUTICAL PRODUCTIONS INC.
Reel/Frame 035875/0936 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 27, 2015
From: MCCARTY, JOHN A.
To: PHARMACEUTICAL PRODUCTIONS, INC.
Reel/Frame 035059/0203 →
Continuity (4)
Continuation 13633924 · Oct 3, 2012
Continuation 12595183
Provisional Application 60922921 · Apr 11, 2007
Related Publication 20150174101A1 · Jun 25, 2015